Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance
- PMID: 16436713
- PMCID: PMC1366932
- DOI: 10.1128/AAC.50.2.580-586.2006
Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance
Abstract
Candida albicans ERG3 encodes a sterol C5,6-desaturase which is essential for synthesis of ergosterol. Defective sterol C5,6 desaturation has been considered to be one of the azole resistance mechanisms in this species. However, the clinical relevance of this resistance mechanism is still unclear. In this study, we created a C. albicans erg3/erg3 mutant by the "Ura-blaster" method and confirmed the expected azole resistance using standard in vitro testing and the presence of ergosta-7,22-dien-3beta-ol instead of ergosterol. For in vivo studies, a wild-type URA3 was placed back into its native locus in the erg3 homozygote to avoid positional effects on URA3 expression. Defective hyphal formation of the erg3 homozygote was observed not only in vitro but in kidney tissues. A marked attenuation of virulence was shown by the longer survival and the lower kidney burdens of mice inoculated with the reconstituted Ura+ erg3 homozygote relative to the control. To assess fluconazole efficacy in a murine model of disseminated candidiasis, inoculum sizes of the control and the erg3 homozygote were chosen which provided a similar organ burden. Under these conditions, fluconazole was highly effective in reducing the organ burden in both groups. This study demonstrates that an ERG3 mutation causing inactivation of sterol C5,6-desaturase cannot confer fluconazole resistance in vivo by itself regardless of resistance measured by standard in vitro testing. The finding questions the clinical significance of this resistance mechanism.
Figures





Similar articles
-
Azole resistance by loss of function of the sterol Δ⁵,⁶-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence.Antimicrob Agents Chemother. 2012 Apr;56(4):1960-8. doi: 10.1128/AAC.05720-11. Epub 2012 Jan 17. Antimicrob Agents Chemother. 2012. PMID: 22252807 Free PMC article.
-
Amino acid substitutions in the Candida albicans sterol Δ5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence.J Antimicrob Chemother. 2012 Sep;67(9):2131-8. doi: 10.1093/jac/dks186. Epub 2012 Jun 7. J Antimicrob Chemother. 2012. PMID: 22678731
-
Loss of Upc2p-Inducible ERG3 Transcription Is Sufficient To Confer Niche-Specific Azole Resistance without Compromising Candida albicans Pathogenicity.mBio. 2018 May 22;9(3):e00225-18. doi: 10.1128/mBio.00225-18. mBio. 2018. PMID: 29789366 Free PMC article.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Antifungal Compounds against Candida Infections from Traditional Chinese Medicine.Biomed Res Int. 2017;2017:4614183. doi: 10.1155/2017/4614183. Epub 2017 Dec 28. Biomed Res Int. 2017. PMID: 29445739 Free PMC article. Review.
Cited by
-
The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney.PLoS Pathog. 2016 Nov 4;12(11):e1005952. doi: 10.1371/journal.ppat.1005952. eCollection 2016 Nov. PLoS Pathog. 2016. PMID: 27814401 Free PMC article.
-
Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans.J Antimicrob Chemother. 2020 Feb 1;75(2):257-270. doi: 10.1093/jac/dkz400. J Antimicrob Chemother. 2020. PMID: 31603213 Free PMC article. Review.
-
Fitness trade-offs restrict the evolution of resistance to amphotericin B.PLoS Biol. 2013 Oct;11(10):e1001692. doi: 10.1371/journal.pbio.1001692. Epub 2013 Oct 29. PLoS Biol. 2013. PMID: 24204207 Free PMC article.
-
Global analysis of genetic circuitry and adaptive mechanisms enabling resistance to the azole antifungal drugs.PLoS Genet. 2018 Apr 27;14(4):e1007319. doi: 10.1371/journal.pgen.1007319. eCollection 2018 Apr. PLoS Genet. 2018. PMID: 29702647 Free PMC article.
-
The development of fluconazole resistance in Candida albicans - an example of microevolution of a fungal pathogen.J Microbiol. 2016 Mar;54(3):192-201. doi: 10.1007/s12275-016-5628-4. Epub 2016 Feb 27. J Microbiol. 2016. PMID: 26920879 Review.
References
-
- Anderson, J. B. 2005. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat. Rev. Microbiol. 3:547-556. - PubMed
-
- Aoyama, Y., Y. Yoshida, and R. Sato. 1984. Yeast cytochrome P-450 catalyzing lanosterol 14 alpha-demethylation. II. Lanosterol metabolism by purified P-450(14)DM and by intact microsomes. J. Biol. Chem. 259:1661-1666. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous